BiotechReadouts
Get updates

Vertex Pharmaceuticals (VRTX): next trial readout expected around 2026-09-17

$VRTX · Vertex Pharmaceuticals IncorporatedTrials that could report in the next 12 months: 24
BiopharmaCTG

Catalyst timeline

Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything VRTX is running — see methodology.

  1. 2026-09-17in 4wAn Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
  2. 2026-10-30in 10wA Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
  3. 2026-11-19in 13wDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
  4. 2026-12-30in 19wInaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
  5. 2027-01-25in 23wEvaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
  6. 2027-01-30in 23wEvaluation of Pain Treatment After Total Knee Arthroplasty
  7. 2027-02-02in 24wA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
  8. 2027-02-26in 27wEvaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
  9. 2027-03-05in 28wA Phase 1, First-in-human Study of VX-433
  10. 2027-03-12in 29wA Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
  11. 2027-03-23in 31wDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
  12. 2027-03-25in 31wEvaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
  13. 2027-04-06in 33wEvaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
  14. 2027-04-06in 33wStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
  15. 2027-05-31in 41wEvaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
  16. 2027-06-06in 42wEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
  17. 2027-06-09in 42wEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
  18. 2027-06-30in 45wA Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
  19. 2027-07-22in 48wPhase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
  20. 2027-09-30in 58wEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
  21. 2027-11-14in 65wEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
  22. 2028-06-02in 93wPhase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
  23. 2028-12-29in 123wEvaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
  24. 2029-03-02in 132wA Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Pipeline

ProgramPhaseStatusPrimary completionTrial
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized My…Phase 2Recruitingstill enrolling patients2029-03-02NCT07501702
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Pa…Phase 2Recruitingstill enrolling patients2028-12-29NCT07204275
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants…Phase 2Recruitingstill enrolling patients2028-06-02NCT05312879
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants …Phase 3Active Not Recruitingenrolled, still running2027-11-14NCT05356195
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic F…Phase 3Active Not Recruitingenrolled, still running2027-09-30NCT06460506
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset …Phase 2Active Not Recruitingenrolled, still running2027-07-22NCT07161037
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants W…Phase 3Recruitingstill enrolling patients2027-06-30NCT04786262
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Partic…Phase 3Recruitingstill enrolling patients2027-06-09NCT05477563
+ 16 more tracked trials
ProgramPhaseStatusPrimary completionTrial
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants …Phase 3Active Not Recruitingenrolled, still running2027-06-06NCT05329649
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated W…Phase 3Recruitingstill enrolling patients2027-05-31NCT06628908
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associ…Phase 3Recruitingstill enrolling patients2027-04-06NCT07231419
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-…Phase 3Active Not Recruitingenrolled, still running2027-04-06NCT05331183
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With D…Phase 2Recruitingstill enrolling patients2027-03-25NCT06619860
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX…Phase 1Recruitingstill enrolling patients2027-03-23NCT07437105
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants W…Phase 1Active Not Recruitingenrolled, still running2027-03-12NCT05791201
A Phase 1, First-in-human Study of VX-433Phase 1Recruitingstill enrolling patients2027-03-05NCT07584434
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy…Phase 1Recruitingstill enrolling patients2027-02-26NCT07378865
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystro…Phase 1Recruitingstill enrolling patients2027-02-02NCT06185764
Evaluation of Pain Treatment After Total Knee ArthroplastyPhase 4Recruitingstill enrolling patients2027-01-30NCT07538570
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (S…Phase 3Active Not Recruitingenrolled, still running2027-01-25NCT06696443
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disea…Phase 2Active Not Recruitingenrolled, still running2026-12-30NCT06794996
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX…Phase 1Recruitingstill enrolling patients2026-11-19NCT07283770
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combina…Phase 3Active Not Recruitingenrolled, still running2026-10-30NCT05444257
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants …Phase 3Recruitingstill enrolling patients2026-09-17NCT06832410

Status-change history

Every ClinicalTrials.gov change recorded for VRTX's trials — a running history no other tracker shows.

No status changes detected yet for this ticker.

Frequently asked

When is VRTX's next PDUFA date?

No disclosed PDUFA date is currently tracked for this ticker.

What phase is VRTX's lead program in?

Phase 3 — recruiting.

Where does this data come from?

ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.